BioSpace3h
Drug Pricing and the Uncertain Future of the IRA Under Trump
While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...
JMP reiterates Kalvista stock with $19 target, sees market growth
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
Pharma landscape points toward need to focus on innovation: Economic Survey 2024-25
There is a need to focus on innovation, new drug development and biopharmaceuticals as spending on research and development still lags behind global leaders, said Economic Survey 2024-25 tabled in ...
stockhead2d
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorder
Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy ...
Targeted Oncology2d
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
stockhead2d
Phase III Trials: It’s crunch time for these ASX health stocks
Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...
BioWorld2d
Seed’s RBM39 degrader awarded US orphan drug, rare pediatric disease designations
Seed Therapeutics Inc.’s ST-01156 has been awarded orphan drug designation for the treatment of Ewing sarcoma as well as rare pediatric disease designation by the FDA.
The American Journal of Managed Care3d
Emerging Therapies Shine Hope on Small Cell Lung Cancer Treatment
Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...
SEED receives FDA Rare Pediatric Disease, Orphan Drug designations for ST-01156
SEED Therapeutics announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease and Orphan Drug designations to ...
TMCnet4d
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
The patent application No. 17/309,952 entitled “An A3 adenosine receptor ligand for use for achieving a fat loss effect”, has been accepted by the US Patent Office, will be issued on February 2 nd and ...
Business Wire7d
ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting
ImmunoMet is also pleased to announce that it has received Orphan Drug Designation status for Lixumistat in patients with pancreatic cancer and glioblastoma multiforme (GBM). ImmunoMet continues to ...